Type-2 diabetes (T2D) mellitus is a complex metabolic disease commonly caused by insulin resistance in 21 several tissues. We performed a matched two-dimensional metabolic screening in tissue samples from a 22 cohort of 43 multi-organ donors. The intra-individual analysis was assessed across five key-metabolic 23 tissues (serum, adipose tissue, liver, pancreatic islets and muscle), and the inter-individual across three 24 different groups reflecting T2D progression. We identified 92 metabolites differing significantly between 25 non-diabetes and T2D subjects. Carnitines were significantly higher in liver, while 26 lysophosphatidylcholines significantly lower in muscle and serum. An investigation of the progression to 27 overt T2D showed that deoxycholic acid glycine conjugate was significantly higher in liver of pre-diabetes 28 samples while additional increase in T2D was insignificant. A subset of lysophosphatidylcholines were 29 significantly lower in the muscle of pre-diabetes subjects. Overall, the analysis of this unique dataset can 30 increase the understanding of the metabolic interplay between organs in the development of T2D. 31
INTRODUCTION 32
Type-2 diabetes (T2D) mellitus is a disease characterized by poor insulin sensitivity and failure of the 33 pancreatic β-cells to secrete appropriate amounts of insulin 1,2 . Insulin resistance (IR) is associated with 34 low physical activity, obesity, dyslipidemia and hypertension 3,4 . T2D is a major global health problem with 35 a reported prevalence of 422 million in 2014 according to the World Health Organization (WHO) 5 . The 36
insulin-related deficiencies in T2D lead to alterations in glucose, fatty acid uptake and metabolism, as well 37
as lipid deposition in different tissues 6 . 38
The field of metabolomics has emerged through the development of high-throughput analytical chemistry 39 techniques 2 . Metabolic profiling enables untargeted screening of a snapshot of the metabolic status for a 40 given sample 7, 8 . Liquid chromatography (LC) coupled with mass-spectrometry (MS) and gas 41 chromatography (GC) coupled with MS are two prominent metabolic profiling technologies covering a 42 wide spectrum of cellular low-weight compounds (<1500 Da) 7 . The untargeted screening is followed by 43 computational "translation" of a subset of the identified compounds into known metabolites 9 . 44 IR in several tissues in combination with insufficient insulin secretion lead to systemic metabolic defects. 45 Multiple studies have attempted to identify potential T2D biomarkers through metabolic profiling of 46 blood, urine or saliva 1,6-8,10-12 . Risk factors identified in biofluids may partly reflect ongoing metabolic 47 processes throughout the body, but are secondary to events occurring in other tissues 13 . Adipose tissue, 48 liver, pancreatic islets and skeletal muscle are well-known to contribute to T2D development 14 , but others 49 like brain and gut are also of importance. 50
In this study we performed a metabolic screening in a cohort of 43 organ donors. The study spanned 51 across five key metabolic tissues (blood serum, intra-abdominal/visceral adipose tissue (VAT), liver, 52 pancreatic islets and skeletal muscle) for T2D. The subjects were then in turn carefully matched for age, 53
body-mass index (BMI), gender and per-tissue sample weight across the different phenotypes to 54 accurately capture the metabolic fingerprint of T2D progression. To our knowledge, this is the first 55 attempt to create an intra-individual map of metabolites across various metabolic-relevant tissues for the 56 same cohort of individuals. In total we identified 286 unique metabolites across all tissues, 32% of which 57
were significantly altered between non-diabetes and T2D. Amino acids (AAs) were elevated in VAT, liver, 58 muscle and serum in T2D, and significantly associated to the percentage of glycosylated hemoglobin A1c 59 (HbA1c). Bile acids were similarly higher, but only in liver. We showed that carnitines and 60 lysophosphatidylcholines (LPCs) are the most significantly altered metabolites in muscle, liver and serum 61 in T2D. Finally, we explored the progression to overt T2D and suggest potential biomarkers in the early 62 development of T2D, i.e. from non-diabetes to pre-diabetes to T2D. 63
RESULTS

64
Metabolic profiling 65 We performed an untargeted metabolic profiling with GC-MS and LC-MS for 43 organ donors from 66 healthy, pre-diabetes and T2D cohorts across five metabolic tissues: VAT, liver, pancreatic islets, skeletal 67 muscle and blood serum (Figure 1 ). Samples were matched for BMI, age, gender and per-tissue sample 68 weight (Table 1 ; Supplementary Table S1 ). The putative identity of the metabolites was determined 69 computationally and resulted in 142 and 144 unique metabolites for GC-MS and LC-MS, respectively. The 70 samples were classified in three distinct phenotypes related to the progression of T2D (controls, pre-71 diabetes and T2D). Partial least squares -discriminant analysis (PLS-DA) models showed a higher similarity 72 of pre-diabetes to controls when compared to T2D, hence controls and pre-diabetes subjects were 73 merged into one non-diabetes group and compared to T2D ( 
Alterations of metabolites across tissues in T2D
85
After imputing and transforming the intensities of the metabolites we investigated the partitioning of the 86 samples per tissue (Materials and methods -Data transformation and normalization). Large within-group 87 variation led PCAs towards ambiguous separation (Supplementary Figure S9A ), yet orthogonal PLS-DA 88 ((O)PLS-DA) improved the partitioning of the phenotypic groups (Supplementary Figure S10A ). Covariates, 89
excluding HbA1c and glucose-stimulated insulin secretion (GSIS), were suggested (cf. Methods -Data 90 transformation and normalization; Supplementary Table S2 ; Supplementary Figure S11 ) and proven 91
( Supplementary Table S3 ; Supplementary Figures S9B and S10B) to maintain the separation seen in the 92 scaled and log2-transformed raw intensities ( Supplementary Figures S9A and S10A ). Correcting for BMI, 93
age, gender and sample weight did not yield extensive alterations in the set of significantly varying 94 metabolites across tissues (Supplementary Figure S12B ). 95
Next, we sought to explore the statistical significance and the direction of the variation of the 96 computationally annotated metabolite intensities between non-diabetes and T2D ( Figure 2 ). More than 97
half of the total number of significant metabolites belonged to the taxon of lipids and lipid-like molecules, 98
which mainly consisted of LPCs, carnitines and free fatty acids (FFAs). Specifically, LPCs were 99 overrepresented in muscle and serum (p-value<10 -132 ), while carnitines were abundant in liver (p-100 value<10 -132 ) ( Supplementary Table S4 ; Supplementary Figure S13 ). We further observed that LPCs and 101 carnitines in serum followed similar patterns with muscle and liver, respectively ( Figure 2 ). Various FFAs 102
were noticed as significant among liver, muscle and serum ( Figure 2 ). 103
Other important groups of metabolites were those of AAs and nucleosides, nucleotides and analogues. 104 We additionally observed that glucose 6-phosphate levels were significantly higher in VAT and liver, while 105 in muscle they were significantly lower, similarly to fructose 6-phosphate ( Figure 2 ). These metabolites, 106 together with ribose 6-phosphate that is also significantly lower in muscle of T2D, are part of the pentose 107 phosphate pathway that has been extensively linked to T2D 15 . 108 109 Carnitine represents a crucial trait d'union between carbohydrate and fatty acid (FA) metabolism. 110
Regulation of carnitine and choline pathways
Carnitine facilitates the transport of FAs into the mitochondria for β-oxidation, but it is also involved in 111 glucose metabolism regulating the pool of acetyl-CoA in the cytoplasm. 112
In our samples, we observed a significant increase in the pool of short-and medium-chain carnitines in 113 liver in T2D and a similar trend in pancreatic islets and serum. Instead, a trend towards reduction of 114 carnitines was observed in muscle and in particular very short-chain carnitines were significantly reduced 115 in T2D (Figures 2 and 3 ). 116
The complexity of the molecular mechanisms behind the association of carnitines to T2D was highlighted 117 using a systems biology approach by Bene et al 16 . They showed that individuals with T1D or metabolic 118 syndrome share similar levels of medium-and long-chain acyl-carnitines while individuals with T2D or 119 metabolic syndrome have similar levels of short-chain acyl-carnitine. 120
We also found a generalized reduction in LPC levels in both serum and muscle including LPC with a 121 surprisingly wide variety of saturation and desaturation; C14:0, C16:0, C16:1, C17:0, C18:0, C18:1, C18:2, 122 C18:3, C20:4, C20:5, C22:5 and C22:6 ( Figure 3 ). The extent of decrease in LPCs is larger in muscle than in 123 plasma ( Figure 2 ). 124
Increased drive of bile acid pathway in T2D 125 We observed a statistically significant increase in the levels of deoxycholic acid conjugate with glycine or 126 taurine in liver in T2D individuals, whereas the increase of chenodeoxycholic acid conjugates was not 127 reaching statistical significance ( Figure 2 ). Glycodeoxycholate was also higher in liver, muscle and serum, 128
but to a significant level only in liver. Taurine levels were also significantly higher in liver of T2D individuals 129 with a non-statistically significant trend also in pancreatic islets, muscle and serum (Supplementary Figure  130 S14). Taurine, which has been reported to associate to serum glucose levels in animal models 17 , is 131 synthesized in the pancreas from cysteine, an AA we detected as significantly elevated in T2D liver samples 132 ( Figure 2 ; Supplementary Figure S15 ). The pathways of primary bile acids biosynthesis and taurine-133 hypotaurine metabolism were significantly enriched in liver (p-value<2.18×10 -2 ) ( Supplementary Table S5 ; 134
Supplementary Figure S16 ). 135
AAs vary across tissues in T2D
136
High levels of circulating branched-chain AAs (BCAAs) leucine, isoleucine, valine and the aromatic AAs 137
(AAAs) tryptophan, phenylalanine and tyrosine, have been repeatedly reported in the literature as 138 associated to obesity, impaired fasting glucose and T2D 18 . Although the differences in BCAA and AAA did 139 not cross the statistical significance threshold levels between control and T2D individuals, we observed a 140 higher level of valine and isoleucine in serum in T2D (Supplementary Figure S17 ). The same trend was 141 observed in VAT. In liver and pancreatic islets the levels of valine, isoleucine and leucine were higher in 142 T2D, while in muscle BCAAs were depleted in T2D (Supplementary Figure S17 ). Tyrosine levels were 143 elevated in VAT, muscle and serum and phenylalanine was higher in T2D liver, pancreatic islets and VAT 144 samples (Supplementary Figure S17) . 145
Adams and colleagues utilized plasma metabolite patterns to target muscle-specific metabolites in 146
African-American females with significantly reduced whole-body lipid oxidation 6 . They found that higher 147 levels of leucine and valine were strongly correlated with acetyl-carnitine, which we found significantly 148 lower in muscle in T2D (Figures 2 and 3 ). Here we observed leucine, isoleucine and valine to be strongly 149 correlated to acetyl-carnitine in muscle (Spearman correlation r>0.65, p-value<0.0102), which was also 150 correlated to propionyl-carnitine (Spearman correlation r=0.64, p-value<0.0161), a marker of valine's 151 catabolic product propionyl-CoA 6,10 . 152
Linear regression models showed that HbA1c was associated to various BCAAs and AAAs for VAT, liver, 153 muscle and serum. Specifically, we observed that tyrosine, phenylalanine, leucine and isoleucine in VAT 154
were significantly associated with HbA1c ( Figure 4A ). Tyrosine and leucine shared the same significant 155 pattern in VAT and serum ( Figure 4A ; Supplementary Figure S17 ). Interestingly tryptophan was significant 156
for muscle and serum in T2D ( Figure 2) , and significantly associated with HbA1c in muscle, liver and serum, 157
sharing an increasing pattern in liver and muscle, while decreasing in serum (Figures 2 and 4A; 158
Supplementary Figure S15 ). Elevated levels of tryptophan in serum is associated to T2D, making it a 159 potential risk predictor for the pathogenesis of T2D 19 . There is increasing evidence pointing towards links 160 between inflammatory processes and tryptophan-related metabolites, e.g. kynurenine that was higher in 161
VAT, liver and muscle of T2D, but did not cross significance threshold (Supplementary Figure S15 ) 20 . 162
We also took advantage of the recent development of an R tool MoDentify 21 to scan for metabolites 163 correlated to the phenotype as single entities or as members of functional modules 22 . This analysis on the 164 full set of AAs revealed phenotype-driven functional modules, where single metabolites that are not 165 directly correlated to T2D form combinatorial modules which are significantly associated to the 166 phenotype. A large number of BCAAs and AAAs, together with other AAs, that are significant either 167 individually or as part of modules were shown to be associated with T2D. They include, among others, 168 leucine, isoleucine, tyrosine and glycine (Supplementary Figure S18 ). 169
Various other AAs have been associated to pre-diabetes or T2D with less consistency 23 . Particularly higher 170 levels of alanine, serine, proline, glutamine, the glutamine/glutamate ratio, glutamate, histidine and 171 lysine. Here we observed significantly higher levels of alanine, glutamine, glutamate, proline and serine in 172 liver; significantly lower levels of proline and higher levels of serine in VAT; and significantly higher levels 173 of histidine in muscle in T2D (Figure 2 ; Supplementary Figure S15 ). Higher levels of glutamate have been 174 linked to diabetes due to its function as a substitute energy source to glycolysis or β-oxidation 2 . 175
Significantly lower levels of methionine and lysine were observed in T2D VAT and muscle, respectively 176 ( Figure 2 ; Supplementary Figure S15 ). Methionine and lysine are precursors involved in the endogenous 177 synthesis of L-Carnitine which was also significantly lower in T2D muscle tissues ( Figure 2 ). 178 179 Metabolite classification analysis revealed that VAT, liver, muscle and serum are enriched for AAs and 180 various types of lipids. Specifically, VAT and serum were enriched for AAs (p-value<1.15×10 -3 ). Liver and 181 muscle were enriched for AAs and derivatives (p-value<1.13×10 -7 ), and acyl carnitines (p-value<2.3×10 -7 ). 182
FA-related pathways are enriched in T2D across tissues
Muscle was highly enriched for LPCs, similar to serum (p-value<10 -132 ) ( Supplementary Table S4 ; 183
Supplementary Figure S13 ). A pathway enrichment analysis showed various pathways related to lipids and 184 lipid-like molecules, such as glycerophospholipid metabolism in liver (p-value<4.63×10 -4 ), biosynthesis of 185 unsaturated FAs in muscle (p-value<1.1×10 -3 ) and carnitine synthesis in serum (p-value<1.59×10 -2 ) 186
( Supplementary Table S5 ; Supplementary Figure S16 ). Overall, liver was the tissue with the largest number 187 of significant metabolic pathways, followed by muscle, VAT and serum (Supplementary Figure S19 ). 188
Liver, muscle and serum showed a strong enrichment in biological roles that are strongly connected to 189 functionalities of lipids and lipid-like molecules in cells, such as lipid catabolism, fatty acid transport, 190 energy production (p-value<9.48×10 -5 ). Muscle metabolites were enriched in unsaturated fatty acids (p-191 value<1.99×10 -2 ), and together with serum in membrane components and energy sources (p-192 value<8.09×10 -2 ) ( Supplementary Table S6 ; Supplementary Figure S20 ). VAT, liver and muscle also showed 193 enrichment for essential AAs (p-value<4.03×10 -10 ), and for various other AA-related biological roles (p-194 value<1.08×10 -3 ) ( Supplementary Table S6 ; Supplementary Figure S20 ). 195
We used MoDentify to confirm that similar metabolites and classes of metabolites were correlated 21 196
( Supplementary Figures S21 and S22 ). Interestingly, we also observed a higher correlation of metabolites 197 within tissues, rather than among tissues (Supplementary Figure S23 ). The most enriched correlation was 198 that of metabolites belonging to the class of lipid and lipid-like molecules ( Supplementary Figures S23 and  199 S24). 200
Rule-based classification suggests combinations of metabolites that define type-2 201 diabetes patients 202 We performed a multivariate statistical analysis to verify metabolites identified by the earlier univariate 203 analysis and to discover new metabolites that were non-linearly associated with T2D in various tissues. 204
Indeed, a subset of LPCs was also marked as significant by the multivariate statistical approach in muscle 205 and serum. In agreement with the previous analysis, proline was found significant in liver, while lysine and 206 histidine in muscle. Proline was also marked as significant for muscle, even though the univariate 207 approach did not mark it as such. Threonine and asparagine were found as significant in discerning 208 between non-diabetes and T2D in VAT (Supplementary Figure S25) . 209
We next used the set of "all-relevant" selected metabolites from above as input to the ROSETTA machine-210 learning approach that produces transparent classification models to uncover combinations of variables 211 that discriminate between phenotypes 24,25 . The computational models for liver, muscle and serum were 212 of high quality (accuracy>80%), while those for VAT and pancreatic islets performed adequately well 213
( Supplementary Table S8 ) given the complexity of the data and the sample size. Rough-set classification 214 models consist of IF-THEN rules, which in addition to being legible, can be visualized into networks 215
( Supplementary Table S9 ). Such networks show combinations of metabolites and their levels that differ 216 between T2D and non-diabetes. In muscle combinations of high levels of palmitic acid and histidine, 217
together with low levels of lysine and LPC(22:6) predict T2D, while average levels of LPC(22:6), mannitol 218
and lysine predict non-diabetes (Supplementary Figure S26) . In liver various levels of adenosine 219 monophosphate in combination with other AAs such as proline and alanine play a central role in deciding 220
for T2D or non-diabetes (Supplementary Figure S26) . 221
Progression of T2D through pre-diabetes 222 In order to identify potential early markers of T2D we applied two different approaches. We used the 223 group of pre-diabetes to monitor the development of metabolites through pair-wise comparisons of the 224 significance between controls and pre-diabetes, as well as between pre-diabetes and T2D. We also 225 expressed HbA1c, a marker of pre-diabetes, as a function of various metabolites via linear regression 226 models (cf. Materials and methods). 227
We first explored the separation among the three phenotypes through PCA and (O)PLS-DA, and observed 228 that the separation was not satisfactory ( Supplementary Figures S1 and S2 ). This occurred mainly due to 229 the limitations in statistical power and the large variation of the metabolite levels. The analysis of T2D and 230 the group of pre-diabetes revealed that 45% of the significantly altered metabolites belonged to the class 231 of lipids and lipid-like molecules (Supplementary Figure S27A) . A large proportion of these metabolites 232 were significant when comparing pre-diabetes to T2D, but not when comparing controls and pre-diabetes. 233
Liver showed a strong enrichment in significantly increased carnitines, FFAs and various AAs in T2D, which 234
were also associated with HbA1c ( Figure 4A; Supplementary Figure S27A ). Compounds belonging to the 235 class of nucleosides, nucleotides and analogues in muscle and six different LPCs in serum were significantly 236 lower in T2D (Supplementary Figure S27A) . We also observed an extended association of various AAs, 237
including several BCAAs and AAAs, with HbA1c ( Figure 4A ). 238
In contrast to serum, various LPCs and FFAs in muscle showed a significant decrease in pre-diabetes when 239 compared to controls, while the same compounds did not further alter or decrease in T2D ( Figure 4B -D; 240
Supplementary Figure S27A ). Such a large collection of events of deregulation in pre-diabetes in 241 combination with the large proportion of LPCs associated with HbA1c suggested that specific LPCs in 242 muscle might be early predictors for T2D ( Figure 4A-D) . In serum and liver, it is also worth to observe that 243 the levels of the bile acids pool increased between control and pre-diabetes while maintaining an elevated 244 level in T2D subjects ( Figure 4E; Supplementary Figure S27A ). Changes in taurodeoxycholic acid, taurine 245 and deoxycholic acid glycine conjugate were also significantly associated to the HbA1c values in the liver 246 ( Figure 4A ). This provides additional evidence that imbalance of the cholesterol metabolism could 247 represent an early marker of T2D. 248
DISCUSSION
249
We performed an extensive metabolomics analysis in a unique collection of five tissues of key importance 250 for T2D. To our knowledge, this is the first attempt to investigate such a wide range of metabolic profiles 251 across tissues in T2D. In total 32% of all the detected metabolites were significant in at least one tissue 252 when comparing non-diabetes to T2D. Generally, the levels of metabolites in liver and muscle, the two 253 major insulin sensitive tissues, demonstrated divergent patterns, with metabolites in liver mainly 254 increasing and the ones in muscle decreasing, potentially reflecting impaired tissue-specific IR and/or 255 metabolic control ( Figure 2) . We also observed a total increase of BCAAs and their associations with 256
HbA1c, previously connected with IR in various tissues 18 ( Figure 4A ; Supplementary Figures S15 and S17 ). 257
Reduced alanine levels in muscle and higher in liver in T2D, suggested an overall increase in the glucose-258 alanine cycle (Figure 2; Supplementary Figure S15 ). 259
Various AAs, including BCAAs and AAAs, were significantly associated with HbA1c in VAT which clinically, 260
is more interesting and relevant to T2D than subcutaneous adipose tissue (SAT). The VAT depot is overall 261 more closely linked to IR and T2D phenotype, with potential causal effects on disturbing hepatic glucose 262 metabolism in prediabetes 26 . Petrus et al. have earlier shown that adipose tissue depots differ in lipid and 263 fatty acid composition, which may be due to distinct enzymatic activity, lipolytic function or gene 264 expression 27 . Hence, our findings in VAT may not apply to other adipose depots such as SAT. 265
The largest class of metabolites that was altered in T2D samples was that of lipid and lipid-like molecules, 266
with LPCs and carnitines highly enriched, and sharing patterns seen in serum with muscle and liver, 267 respectively (Figures 2 and 3) . Plasma LPC levels are determined by lecithin-cholesterol acyltransferase 268 (LCAT) activity, hepatic secretion and phospholipase A2 synthesis from PC 28 . Reduction of LPCs in plasma 269
has been reported to be tightly associated with obesity 28,29 or IR 1,30-32 . The observed systematic decrease 270
in LPCs in both muscle and plasma when comparing the T2D and control subjects may be a strong indicator 271 of diabetes progression (Figures 2 and 3) . Interestingly, here we detected LPCs to significantly decrease in 272 muscle of pre-diabetes and to further decrease in T2D, even though insignificantly ( Figure 4B The endogenous carnitine pool is for the major part located in skeletal muscle. Carnitines and acyl-276 carnitines are also present in the gastrointestinal tract, the liver and the kidneys. Metabolic changes can 277 affect the carnitine pools in the various tissues, but the homeostasis can vary between tissues so that for 278 example, changes in carnitine content in liver rapidly appear in plasma, whereas changes in skeletal 279 muscle content may not be as readily detected 33 . Most of the metabolic studies of the correlation 280 between carnitines, IR and T2D so far relied on analyses of urine, serum and plasma. Here we extended 281 the analysis of the carnitine pool in T2D in other relevant tissues such as liver, muscle, VAT and pancreatic 282 islets (Figures 2, 3 and 4A ). 283
Alterations in the levels of long and medium chain acyl-carnitines, including octadecenoyl-carnitine 284 (C18:1), tetradecenoyl-carnitine (C14:1), tetradecadienoyl-carnitine (C14:2) and short chain acyl-285 carnitines, such as malonyl-carnitine/hydroxybutyryl-carnitine (C3DC+C4OH), have been reported both in 286 T2D and pre-diabetes states in serum 3,10,34,35 . Here we observed a general increase in the short and 287 medium-chain carnitines in liver in T2D, and a similar pattern in serum and pancreatic islets (Figures 2, 3  288 and 4A; Supplementary Figure S27A ). Accumulation of long-chain acyl-carnitines and acyl-carnitine-289 species in T2D plasma might reflect an increased, yet incomplete, mitochondrial β-oxidation with even-290 chain acyl-carnitines, up to 20 carbons, resulting from the initial rounds of oxidation and odd-chain species 291 associated to AA catabolism. The deregulation of β-oxidation seems to be unrelated to the activity of the 292 carnitine acyltransferase I (CPT1) enzyme 36 . Additionally, 3-hydroxybutyric acid, a member of the ketone 293 bodies, whose increase is known to be associated with enhanced β-oxidation, was higher in muscle and 294 significantly higher in liver and serum ( Figure 2 ) 37,38 . 295
Bile acids have been associated with the regulation of cholesterol catabolism, lipid-absorption, 296
homeostasis of triglycerides and glucose. They can also act as hormones regulating various metabolic 297
processes. T2D has been linked to variation of the bile acids pool composition, in particular the ratio of 298 the pool of cholic and deoxycholic acid in the liver to chenodeoxycholic acid in the intestine is reported to 299 be a metabolic signature of impaired cholesterol catabolism in T2D. Evidence in animal models and human 300 points to a higher level of cholic acid synthesis in T2D, which in turn increases the level of deoxycholic 301 acid 4,39,40 . Here we observed higher levels of bile acids in liver, muscle and serum of T2D ( Figure 2 ; 302 Supplementary Figure S14) . A closer look at the levels of bile acids revealed strong correlations to HbA1c 303 and increased levels in liver and serum in pre-diabetes and T2D ( Figures 4A and 4E; Supplementary Figure  304 S27A). 305
Carbohydrate metabolites such as glucose-and fructose-6-phosphate are increased in VAT, liver and 306 serum, but reduced in muscle in T2D. This might reflect reduced metabolism in muscle due to IR and 307 increased supply to other organs (Figure 2 ). Decanoyl-carnitine and deoxycholic acid glycine conjugate 308
show the same significantly increased pattern in serum and liver of pre-diabetes ( Supplementary Figure  309 S27A). These serum markers might reflect their corresponding levels in liver as potential early markers for 310 IR. 311
Despite the novel findings on metabolite changes across several tissues, this study has clear limitations. 312
Due to ethical restrictions, we did not have access to all confounding factors. Hence, there are likely effects 313 due to the acute disease conditions as well as medications and other interventions at the intensive care 314 unit, including metabolic effects of stress. The results need to be confirmed in other settings, e.g. in 315
cohorts of deceased donors with a larger set of potentially confounding factors. There was also lack of 316 statistical power due to the limited collection of samples and, moreover, causality could not be inferred. 317
Instead we explored sets of potential biomarkers that differed between pre-diabetes or T2D. Increasing 318 the number of samples would partly overcome this limitation, and allow future investigations of the 319 dysregulated molecular mechanisms. Further limitations are due to the complex extraction of metabolites 320 from VAT, the relative compound quantification from MS and the uncertainty of the computational pairing 321 of peaks to compounds. However, these limitations are expected to be addressed together with the 322 constant advancements in the field of MS and standardization of complex sample preparation protocols. 323
MATERIALS AND METHODS
324
Ethics statement 325 The consent to use the organs of donors for scientific research was obtained from an online database that 326 is documented to be in full accordance with the regional standard practices and the Swedish law or 327 verbally by the physician in charge from the closest relatives of the deceased person. The tissue samples 328
were acquired and stored at the Excellence of Diabetes Research in Sweden (EXODIAB) biobank. EXODIAB 329 provided the samples that we further stored and analyzed in agreement with the Uppsala Regional Ethics 330
Committee approval (Dnr: 2014/391). 331 332 Samples from three different phenotypic groups (healthy controls, pre-diabetes and T2D) were acquired 333 from frozen portions of five metabolically-relevant human tissues (intra-abdominal/visceral adipose 334 tissue (VAT), liver, pancreatic islets, abdominal skeletal muscle and blood serum) from the EXODIAB 335 biobank. The distribution of the individuals and the tissues over the phenotypes is shown in Figure 1 . 336
Sample collection and processing
Samples were matched for BMI, age, gender and per-tissue sample weight (Table 1 ; Supplementary Table  337 S1). T2D patients were identified based on their medical records at the corresponding medical facilities 338
according to the WHO guidelines 5 . Pre-diabetes patients were defined by the percentage of HbA1c level 339 (5.7 % mmol/mol ≤ HbA1c ≤ 6.5 % mmol/mol) in blood (Table 1) . Samples with HbA1c<5.7 % mmol/mol 340 were classified as controls (Table 1) . Controls and pre-diabetes were merged into one group (non-341 diabetes) into a primary analysis, and their metabolic profiling was compared to the one of T2D. Merging 342 was decided based on PLS-DA models that showed a higher similarity of pre-diabetes to controls when 343 compared to T2D, and for gain of statistical power ( Supplementary Figures S1A-B) . We also measured the 344 GSIS in pancreatic islets that proved to be correlated to be impaired in T2D patients 41 (Table 1;  345  Supplementary Table S1 ; Supplementary Figure S11 ). In secondary analyses, we also examined all three 346 groups separately. 347
Metabolic profiling 348 Metabolic profiling with GC-MS and LC-MS was performed at the Swedish Metabolomics Center in Umeå, 349
Sweden. Detailed information about sample preparation, mass spectrometry and targeted data 350 processing is available at (Supplementary Note -Metabolic Profiling). The remaining supernatants of each 351 tissue type were pooled and used to create tissue-specific quality control (QC) samples. Tandem mass 352 spectrometry analysis (LC-MS only) was run on the QC samples for identification purposes . The samples  353 were analyzed in per-tissue batches according to a randomized run-order on both GC-MS and LC-MS. 354 355 log2 transformation was applied to the whole dataset after missing values were replaced by 1.00001 to 356
Data transformation and normalization
avoid negative values. The transformation assisted in achieving a better approximation of a normal 357 distribution and avoiding bias by outliers 7 . Quantifications from GC-MS and LC-MS were merged into one 358 dataset and metabolite intensities were scaled to μ=0 and σ=1 42 . 359
ISs from MS were also included to the set of covariates, while HbA1c and GSIS were excluded due to their 360 correlation to the outcome (Table 1 ; Supplementary Table S1 ; Supplementary Figure S11 ). Assessment for 361 the contribution of covariates to the separation of samples into groups was performed by applying a 362 generalized linear model that employs a maximum likelihood optimization approach (glmnet) 43 . Glmnet 363 combines the advantages of least absolute shrinkage and selection operator (lasso) that tends to select 364 the most correlated covariate and ridge penalty that tends to shrink the coefficients of the correlated 365 covariates, and take advantage of their potentially linear combinatorics. We ran glmnet with lasso and 366 ridge penalty contributing equally to the model (α=0.5) on a 10-fold cross validation mode in order to 367 achieve an optimal set of lambda coefficients. The coefficients proved to be unimportant (Supplementary  368  Table S2 ; Supplementary Figures S1B, S2B , S9B and S10B). We further investigated whether the detected 369 metabolites were highly associated to covariates by performing Spearman correlation tests while 370
considering the corresponding false discovery rate (FDR) adjusted p-values ( Supplementary Table S10 ). 371
We first explored the structure of the sets of samples with tissue-specific PCAs ( Supplementary Figures S2  372 and S9). Next we aimed at investigating the separation among phenotypic classes by applying (O)PLS-373 DA 44, 45 . The latter surpasses the requirement of PCA for the variation within the phenotypic groups to be 374 sufficiently smaller than the variation between phenotypic groups. (O)PLS-DA aims at revealing group 375 separations in the score space by employing prior knowledge on the phenotypic group membership while 376 applying an orthogonal signal correction filter to recover for intensity variations that do not correlate to 377 the outcome 42,46 ( Supplementary Figures S1 and S10 ). (O)PLS-DA tissue-specific model quality was 378 assessed based on the prediction performance Q 2 statistic, which underperformed due to the limited 379 population ( Supplementary Table S3 ). 380 381 We applied non-parametric (Wilcoxon-Mann Whitney test) permutation tests to estimate the statistical 382
Statistical analysis
importance of the intensities of the metabolites. We used the R package "coin" 47 that employs Monte 383
Carlo resampling to build the background distribution of the test statistic for a given dataset. We 384 performed 100K permutations and set the threshold for statistical significance to 0.1. We additionally 385
computed the log2 fold-change and 90% confidence intervals of the average intensities of metabolites for 386 binary phenotypic groups 7 . 387
We applied a similar approach to explore the non-monotonic levels of metabolites for the pair-wise 388 phenotypic groups of controls, pre-diabetes and T2D. Specifically, we explored the progress of T2D; hence 389
we focused on the comparison of controls to pre-diabetes, and pre-diabetes to T2D. For the same purpose 390
we also explored linear regression models of HbA1c expressed as a function of various single metabolites 391
and measured their estimation of the proportion of variance explained by the computed regression 392 equation (R 2 ) and their p-values. For the linear regression models we used the R package lmPerm that 393 uses permutation tests (100K permutations) for the estimation of statistical significance 48 . 394 395 Additionally, we performed a multivariate variable selection analysis using Boruta 24 . Boruta tackles the 396 problem of selecting all-relevant variables that best discern between the phenotypic classes employing 397 random forest classifiers and comparing the relevance of real variables to random synthetic probes. Next 398 we used the selected set of significant metabolites to build tissue-specific classifiers using an R wrapper 399
Multivariate analysis and classification
for the rough-set ROSETTA toolkit 25, 49 . ROSETTA computes classifiers in the form of minimal IF-THEN rules 400 that are used to predict an a priori defined decision, which in this case was non-diabetes or T2D. In the 401 next step the rules were explored in a network format called VisuNet that facilitates visual exploration of 402 the classifier and demonstrates the co-predictive power of combinations of metabolites 50 . 403 404 To maximize the available information for each metabolite we merged two of the current most widely 405 used small molecules databases, the human metabolome database (HMDB) 51 and the chemical entities of 406 biological interest (ChEBI) 52 . We also included information from two metabolic-pathway databases, the 407 Kyoto Encyclopedia of Genes and Genomes (KEGG) 53 and the small molecule pathway database 408 (SMPDB) 54 . Such an integrated database helped us retrieve various information from multiple existing 409 databases for computationally annotated metabolites detected by high-throughput metabolomics 410 technologies ( Supplementary Table S11 ). We implemented a computational tool that converted the 411 information from various metabolomics databases to a unified local collection of data. The tool is available 412 under https://github.com/klevdiamanti/metabolomicsDB. 413
Computational analysis tools
We additionally implemented a computational tool that performed an integrated analysis of the 414 metabolite intensities, and it is freely available under https://github.com/klevdiamanti/MS_targeted. It 415 takes as input a collection of pre-processed metabolite measurements and their identifiers, and it outputs 416 a set of analysis results that include: i) differential statistical analysis; ii) visual exploration of the statistical 417 analysis; iii) correlation of metabolites and covariates; iv) visual exploration of correlations of metabolites 418 and covariates; vi) datasets for machine-learning approaches; v) correlation analysis for pairs of 419 metabolites; vi) overrepresentation of compounds in metabolic pathways; vii) input datasets for 420 MoDentify 21 ; viii) ratio of concentrations for metabolite pairs 55 . 421 Table 1 : Baseline characteristics of the 43 subjects in the cohort. The mean value and the standard 443 deviation are shown for age, BMI, HbA1c and GSIS. Gender is shown as the proportion of females (F) and 444 males (M). Age is expressed in years. BMI is in kg/m 2 . HbA1c is in % mmol/mol. GSIS is mmol in liters of 445 glucose. Non-diabetes is the merged group of controls and pre-diabetes. P-value 3C is the p-value 446 calculated from a Kruskal-Wallis test on controls, pre-diabetes and T2D. P-value 2C is the p-value 447 calculated from a Wilcoxon-Mann Whitney test on non-diabetes and T2D. 448 on the left-454 hand-side contain the 92 metabolites that were significant in at least one tissue. Table columns Metabolomics Data. arXiv 0, 44, doi:arXiv:1710.03443v2 (2018). 604 
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